Lauri Lukka, Maria Vesterinen, Joonas J Juvonen, Satu Palva, J Matias Palva
{"title":"Patients prefer easy adverse event reporting: Observational study within clinical trial.","authors":"Lauri Lukka, Maria Vesterinen, Joonas J Juvonen, Satu Palva, J Matias Palva","doi":"10.1177/20552076251345894","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Digital intervention safety is crucial for regulatory approval and clinical adoption. However, the evaluation and reporting of adverse events (AEs) in clinical trials are often insufficient. Digital qualitative self-reporting could enhance the detection of AEs, but patient preferences for using such channels remain understudied.</p><p><strong>Methods: </strong>This observational study was conducted in Finland between 2022 and 2024 within a randomized controlled trial evaluating the efficacy of <i>Meliora</i>, a game-based digital intervention for patients living with major depressive disorder. We assessed the preferences of 1001 patients for self-reporting AEs across four channels: a prompted, within-intervention questionnaire (CORTO: Contextual, One-item, Repeated, Timely, Open-ended), a Jira questionnaire, email, and phone.</p><p><strong>Results: </strong>148 (14.8%) patients reported AEs during the study. We found a significant imbalance between the channels: 11.3% (<i>n</i> = 113) of patients reported AEs using CORTO, 4.1% (<i>n</i> = 41) using email, 1.1% (<i>n</i> = 11) using Jira, and 0.4% (<i>n</i> = 4) using phone.</p><p><strong>Conclusions: </strong>These findings reveal that patients prefer low-effort methods for reporting AEs and are more likely to report AEs via a prompted, within-intervention questionnaire (CORTO) than through other methods. Integrating qualitative self-report channels into digital interventions may enhance AE detection rates, improve clinical trial safety monitoring, and support post-market surveillance.</p>","PeriodicalId":51333,"journal":{"name":"DIGITAL HEALTH","volume":"11 ","pages":"20552076251345894"},"PeriodicalIF":2.9000,"publicationDate":"2025-05-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12106987/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"DIGITAL HEALTH","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/20552076251345894","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"HEALTH CARE SCIENCES & SERVICES","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Digital intervention safety is crucial for regulatory approval and clinical adoption. However, the evaluation and reporting of adverse events (AEs) in clinical trials are often insufficient. Digital qualitative self-reporting could enhance the detection of AEs, but patient preferences for using such channels remain understudied.
Methods: This observational study was conducted in Finland between 2022 and 2024 within a randomized controlled trial evaluating the efficacy of Meliora, a game-based digital intervention for patients living with major depressive disorder. We assessed the preferences of 1001 patients for self-reporting AEs across four channels: a prompted, within-intervention questionnaire (CORTO: Contextual, One-item, Repeated, Timely, Open-ended), a Jira questionnaire, email, and phone.
Results: 148 (14.8%) patients reported AEs during the study. We found a significant imbalance between the channels: 11.3% (n = 113) of patients reported AEs using CORTO, 4.1% (n = 41) using email, 1.1% (n = 11) using Jira, and 0.4% (n = 4) using phone.
Conclusions: These findings reveal that patients prefer low-effort methods for reporting AEs and are more likely to report AEs via a prompted, within-intervention questionnaire (CORTO) than through other methods. Integrating qualitative self-report channels into digital interventions may enhance AE detection rates, improve clinical trial safety monitoring, and support post-market surveillance.